Evidence map›Paper›PMID 37500964›Full record

ReviewEuropean radiology2023

Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management.

Bachir Taouli, Ahmed Ba-Ssalamah, Julius Chapiro, Jagpreet Chhatwal, Kathryn Fowler, Tae Wook Kang, Gesine Knobloch, Dow-Mu Koh, Masatoshi Kudo, Jeong Min Lee and 10 more

Erratum issuedOpen access · hybridAbstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 9 countries.

Bachir TaouliDepartment of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. bachir.taouli@mountsinai.org.ORCID http://orcid.org/0000-0001-6409-1333
Ahmed Ba-SsalamahDepartment of Biomedical Imaging and Image-guided therapy, Medical University of Vienna, Vienna, Austria.
Julius ChapiroDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, CT, USA.
Jagpreet ChhatwalDepartment of Radiology, Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Kathryn FowlerDepartment of Radiology, University of California San Diego, La Jolla, CA, USA.
Tae Wook KangDepartment of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Gesine KnoblochGlobal Medical and Clinical Affairs and Digital Development, Radiology, Bayer Pharmaceuticals, Berlin, Germany.
Dow-Mu KohDepartment of Diagnostic Radiology, Royal Marsden Hospital, Sutton, UK.
Masatoshi KudoDepartment of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
Jeong Min LeeDepartment of Radiology, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, South Korea.
Takamichi MurakamiDepartment of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.
David J PinatoDepartment of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Kristina I RingeDepartment of Diagnostic and Interventional Radiology, Hannover Medical School, Hannover, Germany.
Bin SongDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Parissa TabrizianRecanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jin WangDepartment of Radiology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.
Jeong Hee YoonDepartment of Radiology, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, South Korea.
Mengsu ZengDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Jian ZhouLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Valérie VilgrainUniversité Paris Cité and Department of Radiology, Assistance-Publique Hôpitaux de Paris, APHP Nord, Hôpital Beaujon, Clichy, France.
Sun Yat-sen University · CNIcahn School of Medicine at Mount Sinai · USSeoul National University Hospital · KRBayer (Germany) · DEHarvard University · USKindai University · JPKobe University · JPMedical University of Vienna · ATMedizinische Hochschule Hannover · DERoyal Marsden Hospital · GBSamsung Medical Center · KRSichuan University · CNUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversité Paris Cité · FRUniversity of California San Diego · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

The 10th Global Forum for Liver Magnetic Resonance Imaging (MRI) was held as a virtual 2-day meeting in October 2021, attended by delegates from North and South America, Asia, Australia, and Europe. Most delegates were radiologists with experience in liver MRI, with representation also from specialists in liver surgery, oncology, and hepatology. Presentations, discussions, and working groups at the Forum focused on the following themes: • Gadoxetic acid in clinical practice: Eastern and Western perspectives on current uses and challenges in hepatocellular carcinoma (HCC) screening/surveillance, diagnosis, and management • Economics and outcomes of HCC imaging • Radiomics, artificial intelligence (AI) and deep learning (DL) applications of MRI in HCC. These themes are the subject of the current manuscript. A second manuscript discusses multidisciplinary tumor board perspectives: how to approach early-, mid-, and late-stage HCC management from the perspectives of a liver surgeon, interventional radiologist, and oncologist (Taouli et al, 2023). Delegates voted on consensus statements that were developed by working groups on these meeting themes. A consensus was considered to be reached if at least 80% of the voting delegates agreed on the statements. CLINICAL RELEVANCE STATEMENT: This review highlights the clinical applications of gadoxetic acid-enhanced MRI for liver cancer screening and diagnosis, as well as its cost-effectiveness and the applications of radiomics and AI in patients with liver cancer. KEY POINTS: • Interpretation of gadoxetic acid-enhanced MRI differs slightly between Eastern and Western guidelines, reflecting different regional requirements for sensitivity vs specificity. • Emerging data are encouraging for the cost-effectiveness of gadoxetic acid-enhanced MRI in HCC screening and diagnosis, but more studies are required. • Radiomics and artificial intelligence are likely, in the future, to contribute to the detection, staging, assessment of treatment response and prediction of prognosis of HCC-reducing the burden on radiologists and other specialists and supporting timely and targeted treatment for patients.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsArtificial IntelligenceContrast MediaGadolinium DTPAHumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyRetrospective StudiesSensitivity and SpecificityContrast MediaGadolinium DTPAgadolinium ethoxybenzyl DTPAGadoxetic acidHepatocellular carcinomaMagnetic resonance imaging

Identifiers

PMID37500964
PMCPMC10730664
OpenAlexW4385330366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.